Dergiler / Turkish Respiratory Journal / 2002 / Cilt: 3 - Sayı: 3

The incidence of hepatitis C virus in patients with lung cancer

Sayfa
91–93
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, further studies which include a larger number of patients with HCV infection are needed to confirm this finding.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Oncogenesis is a multifactorial process affected by environmental, genetic and infectious factors.
📊
Temel Bulgular & Veri:A possible role of some specific viruses has been suggested in at least 15% of human cancer cases.
💡
Sonuç & Katkı:However, further studies which include a larger number of patients with HCV infection are needed to confirm this finding.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Hepatit C antikorları · Akciğer neoplazmları · Hepacivirus

Abstract

Background: Oncogenesis is a multifactorial process affected by environmental, genetic and infectious factors. A possible role of some specific viruses has been suggested in at least 15% of human cancer cases. Objective: The aim of the study was to evaluate the frequency of HCV infection in patients with lung cancer and thus contribute to the documentation of a possible relationship between lung cancer and HCV infection. Methods: Anti-HCV antibodies were measured in sera from 45 patients with lung cancer and in sera from 80 patients with benign lung diseases and 135 healthy individuals. A commercial enzyme linked immunosorbent kit assay was used in the analyses. Results: Anti-HCV antibodies were positive in 6.7% of lung cancer patients while no anti-HCV antibody was detected inpatients with benign lung diseases (p<0.05). In healthy controls, anti-HCV antibodies were positive in one subject (0.7 %). The histopathologic diagnosis of the 3 patients with pos-itive anti-HCV antibodies was non-small-cell cancer squamous cell carcinoma in one case, adenocancer in the second, and adenosquamous cell carcinoma in the third patient). Hepatitis B surface antigen was present in 4 of the 45 patients with lung cancer and in 8 of the 80 benign lung disease cases (p>0.05). Conclusions: The prevalence of anti-HCV positivity in patients with lung cancer was shown to be significantly higher than patients with benign lung disease and healthy individuals in our population. However, further studies which include a larger number of patients with HCV infection are needed to confirm this finding.

🔖

Bu Makaleye Atıf Yap

UZUN, K., ALICI, S., ÖZBAY, B., GENCER, M., IRMAK, H. (2002). The incidence of hepatitis C virus in patients with lung cancer. Turkish Respiratory Journal, Cilt: 3 - Sayı: 3, 91–93. https://ajindex.com/articles/375333

Kaynakça (1)

  1. Beckett WS. Epidemiology and etiology of lung cancer. Clin in Chest Med 1993; 14(1): 1-17 2. Mueller N. Viral agents and cancer. Environ-Health-Perspect. 1995;103(suppl 8): 259-61 3. Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am. J. Gastroenterol. 1997; 92(1): 4-17 4. Egan JJ, Woodcock AA, Stewart JP. Viruses and idiopathic pul¬ monary fibrosis. Eur Respir J. 1997; 10: 1433-37 5. Maddrey WC. Viral hepatitis: A 1994 interim report. Gastroenterol Clin of North Am. 1994; 23(3): 429-35 6. Nagao Y, Sata M, Tanikawa K, Itoh K, Kameyama T. High prevalance of hepatitis C viruc antibodyand RNA in patients with oral cancer. J Oral Pathol. 1995; 24(8): 354-60 7. Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti, Longombardo G, et al. Hepatitic C virus infection in patients with non-Hodgkin's lymhoma. Br J Haematol. 1994; 88: 392-4 8. Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, et al. Idiopathic pulmonary fibrosis and high prevalance of serum anti¬ bodies to hepatitis C virus. Am Rev Respir Dis. 1992; 146: 266-8 9. Talliani G, Poliandri G, Clementi C, et al. Chronic hepatitis C and diabetes mellitus. J Hepatol. 1992; l6(suppl): 116 10. American Thoracic Society/European Respiratory Society. Pretreatment of non-small cell lung cancer. Am J Respir Crit Care.1997; 156:320-32 11. Ferri C, La Civita L, Zignego AL, Pasero G. Viruses and cancers: pos¬ sible role of hepatitis C virus. Eur J Clin invest. 1997; 27(9): 711-8 12. Doğancı L, Haznedaroğlu T. Prevalence of hepatitis A,B and C in Turkey. Eur J Clin Microbiol Infect Dis. 1992; 11(7): 661-2 13- Kasai K, Sato Y, Kameya T, Inoue H, Yoshimura H, Kon S, Kikuchi K. Incidence of latent infection of Epstein-Barr virus in lung can-cers-an analysis of EBER 1 expression in lung cancers by in situ hybridization. J Pathol. 1994; 174(4): 257-65 14. Roy A, Dey S, Chatterjee R. Prevalence of serum IgG and Ig M anti¬ bodies against Epstein-Barr virus capsid antigen in Indian patients with respiratory tract carcinomas. Neoplasma. 1994; 41(1): 29-33 15. Kinoshita I, Dosaka AH, Shindoh M, Fujino M, Akie K, Kato M, Fujinaga K, Kawakami Y. Human papillomavirus type 18 DNA E6- E7 mRNA are detected in squamos cell carcinoma and adenocarci- noma of the lung. Br J Cancer. 1995; 71(2): 344-9 16. Matsuzaki H, Asou N, Kawaguchi Y, Hata H, Yoshinaga T, Kinuwaki E, Ishii T, Yamaguchi K, Takatsuki K. Human T cell leukemia virus type 1 associated with small cell lung cancer. Cancer 1990 Oct 15; 66(8):